Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.
Aoki K, Nishito Y, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Nishizawa T, Fukuda H, Ohashi K, Arai K, Mizoguchi Y, Yoshida Y, Watanabe SI, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Maruyama T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Mizuno H, Tsunoda H, Ochiai A. Aoki K, et al. Among authors: nishito y. Cancer Res Commun. 2023 Jun 13;3(6):1026-1040. doi: 10.1158/2767-9764.CRC-22-0415. eCollection 2023 Jun. Cancer Res Commun. 2023. PMID: 37377611 Free PMC article.
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y, Shiraiwa H, Azuma Y, Tsunenari T, Kayukawa Y, Sonobe Y, Ono N, Sakata K, Fujii T, Miyazaki Y, Noguchi M, Endo M, Harada A, Frings W, Fujii E, Nanba E, Narita A, Sakamoto A, Wakabayashi T, Konishi H, Segawa H, Igawa T, Tsushima T, Mutoh H, Nishito Y, Takahashi M, Stewart L, ElGabry E, Kawabe Y, Ishigai M, Chiba S, Aoki M, Hattori K, Nezu J. Ishiguro T, et al. Among authors: nishito y. Sci Transl Med. 2017 Oct 4;9(410):eaal4291. doi: 10.1126/scitranslmed.aal4291. Sci Transl Med. 2017. PMID: 28978751
Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours.
Sano Y, Azuma Y, Tsunenari T, Kayukawa Y, Shinozuka J, Fujii E, Amano J, Nishito Y, Maruyama T, Kinoshita Y, Sakamoto Y, Yoshida A, Miyazaki Y, Sato Y, Teramoto-Seida C, Ishiguro T, Tanaka T, Kitazawa T, Endo M. Sano Y, et al. Among authors: nishito y. Nat Commun. 2022 Sep 7;13(1):5265. doi: 10.1038/s41467-022-32952-3. Nat Commun. 2022. PMID: 36071036 Free PMC article.
Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion.
Arata Y, Motoyama S, Yano M, Ikuno T, Ito S, Matsushita T, Takeiri A, Nishito Y, Yabuki N, Mizuno H, Sampei Z, Mishima M, Honda M, Kiyokawa J, Suzuki H, Chiba S, Tabo M, Kubo C. Arata Y, et al. Among authors: nishito y. MAbs. 2023 Jan-Dec;15(1):2253570. doi: 10.1080/19420862.2023.2253570. MAbs. 2023. PMID: 37682072 Free PMC article.
Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
Fukuda H, Arai K, Mizuno H, Nishito Y, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Maruyama T, Kuwabara K, Nishizawa T, Mizoguchi Y, Yoshida Y, Watanabe SI, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Ochiai A, Tsunoda H, Aoki K. Fukuda H, et al. Among authors: nishito y. Cancer Sci. 2024 Mar 25. doi: 10.1111/cas.16154. Online ahead of print. Cancer Sci. 2024. PMID: 38527308 Free article.
73 results